Rendi-Wagner Pamela, Kundi M, Zent O, Banzhoff A, Jaehnig P, Stemberger R, Dvorak G, Grumbeck E, Laaber B, Kollaritsch H
Department of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, Medical University of Vienna, Kinderspitalgasse 15, A-1095 Vienna, Austria.
Vaccine. 2004 Dec 9;23(4):427-34. doi: 10.1016/j.vaccine.2004.07.002.
This study investigated the immune response and safety in 430 adults, when boosted more than 3 years after primary or booster TBE immunisation as measured by neutralization test (NT) and ELISA. Tested by NT, the post-booster day 21 geometric mean titer (GMT) was 331 and 142 for the 18-49 and > or =50 years old, respectively. The post-/pre-booster geometric mean titer ratio (GMR) was 2.29 for the 18-49 years old and 3.21 for the > or =50 years old. An at least four-fold increase of neutralizing TBE antibodies was observed in only 26 and 38% of subjects aged 18-49 and > or =50 years, respectively. The booster effect in subjects with only the primary vaccination course prior to study entry clearly depended on the time elapsed since last TBE vaccination with an estimated annual decline rate of 15%. In subjects with at least one additional booster vaccination virtually no antibody decline was observed. This study clearly indicates that (1) adults may be effectively and safely boosted with a different TBE vaccine and (2) following four immunisations protective antibodies can be detected far beyond a period of 3 years, thus, strongly supporting the reconsideration of currently recommended booster intervals.
本研究通过中和试验（NT）和酶联免疫吸附测定（ELISA），调查了430名成年人在初次接种或加强接种蜱传脑炎（TBE）疫苗3年多后进行加强接种时的免疫反应和安全性。通过NT检测，18至49岁和≥50岁人群在加强接种后第21天的几何平均滴度（GMT）分别为331和142。18至49岁人群加强接种后/前几何平均滴度比值（GMR）为2.29，≥50岁人群为3.21。在18至49岁和≥50岁的受试者中，分别只有26%和38%观察到中和性TBE抗体至少增加了四倍。在研究开始前仅接受过初次疫苗接种疗程的受试者中，加强接种效果明显取决于自上次接种TBE疫苗以来的时间，估计年下降率为15%。在至少额外接种过一次加强疫苗的受试者中，几乎未观察到抗体下降。本研究清楚地表明：（1）成年人可以使用不同的TBE疫苗进行有效且安全的加强接种；（2）在四次免疫接种后，可在远超3年的时间内检测到保护性抗体，因此，有力支持重新考虑当前推荐的加强接种间隔。
